You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Protocol initiator, source of founding, nature of BDR, organ and state

From: Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

  All BF OT p value
(n = 245, 100 %) (n = 147, 60 %)c (n = 98, 40 %)d
Protocol initiator     
 Academic 176 (71.8 %) 120 (81.6 %) 56 (57.1 %) <0.001
 Collaborative Groups 42 (17.1 %) 11 (7.5 %) 31 (31.6 %)
 Industry 15 (6.1 %) 13 (8.8 %) 2 (2.0 %)
 NIH 12 (4.9 %) 3 (2.0 %) 9 (9.2 %)
Source of funding     
 Academic 145 (59.2 %) 99 (67.3 %) 46 (46.9 %) <0.001
 Collaborative Groups 13 (5.3 %) 2 (1.4 %) 11 (11.2 %)
 Industry 30 (12.2 %) 25 (17.0 %) 5 (5.1 %)
 NIH 56 (22.9 %) 20 (13.6 %) 36 (36.7 %)
 Public-private part. 1 (0.4 %) 1 (0.7 %) 0 (0.0 %)
Type of BDRa     
Not definedb 83 (33.9 %) 30 (20.4 %) 53 (54.1 %) <0.001
 HDR 75 (46.3 %) 53 (45.3 %) 22 (48.9 %) 0.001
 HDR/LDR 16 (9.9 %) 6 (5.1 %) 10 (22.2 %)
 HDR/PDR 2 (1.2 %) 2 (1.7 %) 0 (0.0 %)
 LDR 68 (42.0 %) 56 (47.9 %) 12 (26.7 %)
 PDR 1 (0.6 %) 0 (0.0 %) 1 (2.2 %)
Country     
 USA 144 (58.8 %) 85 (57.8 %) 59 (60.2 %) 0.219
 Canada 27 (11.0 %) 20 (13.6 %) 7 (7.1 %)
 France 10 (4.1 %) 6 (4.1 %) 4 (4.1 %)
 China 10 (4.1 %) 7 (4.8 %) 3 (3.1 %)
 Germany 10 (4.1 %) 8 (5.4 %) 2 (2.0 %)
 Other 44 (18.0 %) 21 (14.3 %) 23 (23.5 %)
Organ     
 Prostate 80 (32.7 %) 59 (40.1 %) 21 (21.4 %) <0.001
 Cervix uteri 54 (22.0 %) 10 (6.8 %) 44 (44.9 %)
 Breast 29 (11.8 %) 25 (17.0 %) 4 (4.1 %)
 Uterus 14 (5.7 %) 5 (3.4 %) 9 (9.2 %)
 Other 68 (27.8 %) 48 (32.7 %) 20 (20.4 %)
  1. a BDR brachytherapy dose rate, HDR high dose rate, LDR low dose rate, PDR pulse dose rate
  2. bPercentage of total number per column
  3. cBrachytherapy in focus
  4. dOther trials